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Numerous clinical studies and experimental investigations
using cell culture and animal models suggest that
angiotensin II (AngII) via AT1 receptor activation might
induce cardiovascular hypertrophy, fibrosis and
atherosclerosis resulting in vascular events such as
myocardial infarction, heart failure or stroke and in end-
organ damages. However, a question still remains: which part
of these damages is due to a direct effect of AngII on its
target tissues and which is due to AngII-induced
hypertension? In an attempt to answer this question, a new
model of transgenic mice, expressing a constitutively
activated AT1A receptor instead of the wild type receptor has
been obtained by homologous recombination. These mice
present with a moderate increase of blood pressure
(20 mm Hg), hypertrophy of the small kidney arteries but not
cardiac hypertrophy. The major phenotypic trait of these
mice is the early and progressive development of a
cardiovascular fibrosis. In light of these results and those
from the literature, there is more and more evidence that
in human hypertension, activation of the renin angiotensin
system plays a minor role in the development of
cardiovascular hypertrophy, but clearly participates to the
development of cardiovascular fibrosis.
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The major consequences of hypertension are end-organ
damages and cardiovascular complications, such as myocar-
dial infarction (MI), stroke, and heart failure. Diverse
antihypertensive drugs are able to reduce both high blood
pressure (BP) and these complications. However, several
clinical trials point out that there is an additional benefit for
the prevention of cardiovascular diseases to treat patients
with inhibitors of the renin–angiotensin system (RAS), that is
angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs).1 This beneficial effect
was supposed to be the consequence of the inhibition of
specific tissular effects of angiotensin II (AngII) on vascular
structure, atherosclerosis, and cardiac remodeling. Starting
from this concept, numerous in vitro and in vivo studies have
tried to evaluate the precise physiological impact of AngII on
cardiovascular diseases. Most of these studies have limitations
due to the impossibility to dissociate between direct tissular
actions and hypertensive effects of AngII or to eliminate the
involvement of other interfering factors (aldosterone, brady-
kinin, AT2 receptor, and so on).
AngII is the major effector of the RAS and exerts its
physiological actions through membrane-bound receptors of
the G-protein coupled receptor (GPCR) family. There are two
types of AngII receptors, called AT1R and AT2R. Rodent
display two subtypes of AT1 receptors (AT1AR and AT1BR).
2
Without any doubt the AT1 receptor (AT1AR in rodents)
transduces the large majority of the cardiovascular actions of
AngII and therefore the putative roles of AT1BR and AT2R in
the cardiovascular system will be evoked briefly in this review.
During the past years, a major breakthrough in the under-
standing of GPCR functions was the identification of
artificial or natural mutations of these receptors able to
constitutively activate their signaling pathways, indepen-
dently of the mediator.3 Using random mutagenesis, we were
able to identify the mutations that constitutively activate the
angiotensin AT1A receptor.
4 It was then logical to introduce
such mutations in the mouse genome in order to analyze the
pathophysiological consequences of an activated AT1 receptor
expression. Using homologous recombination, the wild-type
(WT) AT1A receptor gene was replaced with a ‘gain of
function’ mutated AT1A receptor gene (AT1AMUT), contain-
ing two mutations: N111S mutation, which constitutively
activates the receptor and a C-terminal deletion, which
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impairs constitutive internalization and desensitization of
this receptor.5 This AT1AMUT mouse model provides new
information on the direct role of AT1 receptor activation in
the development of cardiovascular diseases. This review
focuses and summarizes the experimental data and present
concepts on the role of AT1 receptor activation in the
development of cardiovascular diseases.
Renin–angiotensin system, AT1 receptors, and hypertension
In human, activation of the RAS leads to hypertension in
several situations, including renal artery stenosis.6 The
extensive therapeutic use of RAS inhibitors, such as ACEI
and ARB, in essential hypertension sustains the importance
of the system in BP regulation.7 However, no polymorphism
of the RAS genes (angiotensinogen, renin, and converting
enzyme) has been unambiguously demonstrated to be linked
or associated to hypertension.8 Several studies were unable to
associate consistently hypertension to polymorphisms of the
AT1 receptor gene. In addition, no activating mutation of the
AT1 receptor, which was a logical candidate, has been yet
described in secondary forms of hypertension, such as
primary hyperaldosteronism.9
These results obtained in human pathology suggest an
apparently modest role of the RAS genes in determining
monogenic or polygenic forms of human hypertension and
contrast with results obtained in genetically modified animal
models. Manipulation of the RAS genes in mouse and rat has
comforted the idea that the system is crucial for BP
regulation. Duplications of the angiotensinogen or AT1A
receptor genes create hypertensive mice.10,11 Large over-
expression of renin and angiotensinogen genes in transgenic
rats produced a fulminant hypertension.12 Conversely, the
knockout (KO) of renin, angiotensinogen, converting enzyme
or AT1A receptor genes in mice result in a 20 mm Hg
reduction of BP, whereas AT1BR KO indicates that this
receptor is not involved in BP regulation and cardiovascular
function.13 Similar KO experiments suggest that AT2R
counterbalances the AT1AR pressor action and causes a
reduction in AngII-induced hypertension.14 The predomi-
nant role of AT1AR was recently and very elegantly explored
by kidney crosstransplantation experiments in AT1AKO
and WT mice. In these experiments, Crowley et al.15
demonstrated that BP differences between the two strains
are equally due to kidney and peripheral AT1A receptors, but
that AngII induces hypertension primarily through kidney
receptors.
All these data suggest that a permanent and excessive
activation of the AT1 receptor should result in hypertension.
The definitive demonstration of this hypothesis was obtained
recently in our laboratory. Homozygous knock-in AT1AMUT
mice are viable and present with a permanent higher BP
(þ 20 mm Hg) than WT littermates (Table 1). This BP
elevation is observed as early as five weeks of age, is moderate
and stable during the mouse life and is more pronounced in
male. The logical consequences of this elevated BP and AT1A
receptor activation are a dramatic reduction of plasma renin
concentrations (10% of the WT values) and plasma
immunoreactive AngII (50% of the WT values). However
and unexpectedly, the plasma levels of aldosterone are
identical in WT and AT1AMUT mice and the zona
glomerulosa of the adrenal cortex does not present any
hypertrophy and expresses normal levels of aldosterone
synthase (personal data). As the adrenal cortex is the only
organ expressing equal amounts of AT1A and AT1B receptors,
one can suppose that these normal aldosterone levels result
from equilibrium between a constitutive overactivation of the
mutated AT1A receptor and an underactivation of the WT
AT1B receptor following downregulation of the RAS. Other
regulatory factors independent from the RAS may also be
considered. This normal aldosterone production, despite the
hypertension and the downregulation of the RAS, defines a
relative hyperaldosteronism in AT1AMUT animals (aldoster-
one/renin ratio 10-fold higher in AT1AMUT mice compared
to WT animals).
The reactivity of BP to AngII was investigated in these
different models of mice genetically modified for their AT1
receptors. The amplitude of the BP response is reduced in
AT1AKO mice, suggesting a major role of the AT1A receptor in
mediating this response. The double AT1A/AT1BKO abolishes
the AngII BP reactivity, indicating a compensatory role of the
AT1B receptor.
13
Table 1 | Cardiovascular phenotypes of AT1A transgenic mouse models
Systolic blood
pressure
(mm Hg)
Cardiac phenotype Vascular phenotype
Response
to MI
Response to
pressure
overload
Response to
atherogenic
regimen
Mouse model Hypertrophy Fibrosis Hypertrophy Fibrosis
AT1A knockout 24 NS16 NS16 NS ND Improved
survival
NS16 Inhibition of ApoEKO
atheroscleroses
Cardiac-specific AT1A
overexpression18
ND LV/BW 2.5 Interstitial ND ND ND ND ND
AT1A knock-in mice
(AT1AMUT)
5
+20 NS Perivascular
Interstitial
Media
thickness of
small renal
arteries
Perivascular
(myocardium,
kidney)
ND ND UI (ApoEKO
breeding)
NS, not significant compared to age-matched wild-type animals; ND, not determined; UI, under investigation.
1380 Kidney International (2008) 74, 1379–1384
m i n i r e v i e w S Billet et al.: Role of angiotensin II AT1 receptor activation
Interestingly, in the AT1AMUT, the sensitivity and the
amplitude of the BP response to AngII are both increased. In
addition, the initial increase of the BP is followed by a
plateau, which lasts at least 30 min and results very likely
from the absence of desensitization of the mutated receptor.5
Similar to the permanent hypertension, the increased AngII
sensitivity is moderate. This could be due not only to the
mild constitutive activation of the receptor following the
mutation, but also to an opposite effect of the endothelial-
activated receptor to its hypertensive effect in vascular
smooth muscle cells (VSMCs). Indeed, a recent report by
Karnik’s team demonstrates that overexpression of a
constitutively active mutant (N111G) of the AT1A receptor
in endothelial cells results in a reduction of BP (15 mm Hg),
bradycardia, and hyporeactivity to AngII.19
AT1 receptors and vascular remodeling
Chronic hypertension results in vascular remodeling, includ-
ing VSMC hypertrophy, vascular fibrosis, endothelial dys-
function, and accelerated development of atherosclerosis.
Whether or not this remodeling is the direct consequence of
hypertension, of RAS and AT1 receptor activation or of both
is a long-lasting debate.20 The development of the AT1AMUT
mouse model appears to be a unique opportunity to
investigate this question, as it was designed as a model of
pure and chronic activation of the AT1A receptor.
The possible role of AT1 activation in vascular remodeling
was first suggested in several clinical trials showing that ARBs
were more effective than other antihypertensive drugs in
reducing vascular mortality (stroke and MI) independent of
the BP reduction. For example, the Losartan Intervention for
Endpoint reduction in hypertension study is a large randomized
trial recruiting hypertensive patients, which demonstrates that
losartan allows a significant reduction of the combined end
point of death, stroke, and MI in comparison to atenolol
treatment despite an identical reduction of BP.21 Although
subsequent clinical trials did not always confirm this additional
benefice of AngII blockers depending on the compared
treatments, the studied population or the chosen end points,
they stimulate experimental investigations on the roles of AngII
on vascular tissues in several directions: VSMC growth, peri-
vascular fibrosis, endothelial dysfunction, and atherosclerosis.
There is accumulating evidence that AngII is able to
promote growth of VSMC in cell culture.22 In general, this
growth is limited to cell hypertrophy with increased protein
synthesis, but in a limited number of reports, AngII is also able
to stimulate proliferation (cerebral artery VSMC and mesan-
gial cells). Hypertrophic and hyperplasic effects of AngII on
VSMC involve the activation of the mitogen-activated protein
(MAP) kinase cascade through several signaling pathways
activated by the AT1 receptor, including protein kinase C
activation, epidermal growth factor receptor transactivation,
activation of the Jak–STAT pathway, activation of the reactive
oxygen species, and eicosanoid productions.20 Again, the AT2R
appears to counterbalance the proliferative effect of AngII
through the AT1R in these vascular models.
23
This in vitro action of AngII is less-convincing in vivo in
animal models or in human hypertension. Indirect evidence
comes from clinical studies on small cohorts of patients,
showing for example that ARB is more efficient than a
b-blocker in reducing intima-media thickness, independently
of the BP reduction.24 A more convincing evidence was
brought by the demonstration that arterial thickening and
VSMC proliferation after vascular injury was reduced by
more than 50% in AT1AKO mice compared to WT mice.
25 In
our model of AT1AMUT mice, a moderate but significant
hypertrophy of the small arteries of the kidney was observed
in 5-month-old mice (Table 1). Further investigations are
required to exclude a partial role of the 20 mm Hg elevation
of BP in this process and to investigate this remodeling in
other vascular beds and with other hypertrophy markers.
Similarly, there is no doubt that AngII stimulates in vitro
the production of extracellular matrix (ECM) components by
VSMC (vascular fibrosis) and fibroblasts (perivascular
fibrosis).20 The profibrotic effect of AT1R activation involves
an increased expression of collagens, fibronectin, osteopon-
tin, and proteoglycans and some of these effects are mediated
by an autocrine release of transforming growth factor-b1. In
addition, the ECM degradation seems to be reduced in
VSMC consecutively to a reduction of MMP activation by
plasminogen activator inhibitor-1. The role of the AT1
receptor activation in vascular fibrosis and remodeling was
further demonstrated in animal models. There is accumulat-
ing evidence that treatments of different strains of hyperten-
sive rodents with ACEI or ARB reduce the vascular fibrosis
and remodeling, but these experiments do not demonstrate
the direct involvement of AT1R activation, as these results
may be explained by the reduction of BP, activation of the
bradykinin system or of AT2 receptors.
26 Further evidence of
a possible role of AT1 activation in vascular remodeling could
be suggested by experiments using low, non-antihypertensive
doses of ARB. For example, non-antihypertensive doses of
candesartan reduce perivascular fibrosis induced by suprar-
enal aortic constriction in rat.27 Another strong support of
such a role is given by the protective effect of losartan in the
vascular remodeling observed in the Marfan Syndrome in
absence of any hypertension.28
Interestingly, a premature perivascular fibrosis was
observed in several tissues including the kidney of young
(5-month-old) AT1AMUT mice with a threefold increase of
a1-collagen expression. Further studies are in progress to
determine the time course and the arterial distribution of this
fibrosis. In addition, if the involvement of aldosterone can be
excluded (normal plasma aldosterone levels in AT1AMUT
mice), we cannot exclude the participation of BP in fibrosis
development and long-term reduction of BP in AT1AMUT
mice will answer this question in the near future.
The role of AT1 activation in the initiation and develop-
ment of atherosclerosis has been also investigated using
animal models.29 Bone marrow chimera between WT and
AT1AKO mice demonstrate unambiguously that AT1 recep-
tors of both circulating and vascular cells are involved in
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adhesion of leukocytes to the endothelium and their
activation.30 After the initiation of the atherosclerotic plaque,
its development may also involve AT1 receptor activation in
leukocytes and VSMC by the production of proinflammatory
cytokines, chemokines, reactive oxygen species and other
factors. Breeding of apolipoprotein E and AT1AKO mice
inhibits the diet-induced atherosclerosis normally observed
in apolipoprotein E KO mice.17 Finally, AT1R activation may
also favor plaque rupture and acute events by stimulating
ECM degradation (modification of the balance between the
production of matrix metalloproteases and their tissue
inhibitors) and by stimulating thrombotic events (increase
of plasminogen activator inhibitor-1 expression).31 The
AT1AMUT mice, which express an activated AT1A receptor,
is the perfect model to evaluate in depth the role of this
receptor in the different steps of atherosclerosis development.
AT1 receptors and cardiac remodeling
Besides its role in the development of atherosclerosis in
coronary arteries leading to MI, AT1 receptor activation is
also involved in post-MI cardiac remodeling. Numerous
clinical studies have demonstrated that blockade of the RAS
reduces the morbidity and mortality after MI.32 After MI,
fibroblast AT1 receptor expression increases strongly in the
infarcted and peri-infarcted areas, together with an activation
of the circulating and local components of the RAS, resulting
in a potent activation of the receptors in the heart.33 This
activation might have several short- and long-term con-
sequences. Experimental MI in WT and AT1AKO mice
indicates that AT1 receptor activation has no consequences
on the size of the infarcted area, but increases the frequency
of reperfusion arrhythmias.34 As a long-term effect, AT1
activation stimulates cardiac remodeling after MI. This
remodeling involves both cardiac fibroblasts, which produce
in excess ECM components and cardiomyocytes, which
present hypertrophy and contractility alterations. Interest-
ingly, the AT2R expression is also increased in the peri-
infarcted area and its activation might reduce the effects of
AT1R activation. These modifications of the peri-infarcted
area participate to heart failure, a very classical complication
of MI. Therefore, ACEI or ARB treatment of MI reduces the
occurrence of heart failure, not only by reducing cardiac
overload but also by inactivating the AT1 receptor.
Whatever its origin, heart failure is one of the con-
sequences of pressure overload of the left ventricle. Blocking
the RAS with ACEI or ARB is one of the major treatments of
heart failure, but it is unclear which part is due to pressure
overload or to AT1R activation. The role of AngII as a direct
mediator of left ventricular hypertrophy is questionable.35
On one hand, there is clear evidence that a strong AT1
receptor activation induces cardiac hypertrophy. Overexpres-
sion of the WT AT1A receptor in the heart of transgenic mice
induces a massive cardiac hypertrophy and fibrosis with
conduction and rhythm defects and heart failure without
hypertension (Table 1)36,18 and this phenotype can be
reversed by ARB. However, cardiac overexpression of proteins
unrelated to the heart and even to the mammalian species
(CRE recombinase, green fluorescent protein, or GAL4)
results also in a dilated cardiomyopathy, which can be partly
prevented by ACEI.35 Therefore, it is likely that at least a part
of this cardiopathy is consecutive to the nonspecific
accumulation of the protein in the cardiomyocytes rather
than a specific action of this protein. Interestingly, this AT1
receptor activation in the heart can not only result from a
local production of AngII but also from mechanical stretch,
such as volume overload itself. It has been clearly demon-
strated in vitro that mechanical stretch activates the AT1
receptor and the MAP kinase cascade by Gq protein-
dependent and Jak–STAT signaling pathways.37 In cell
cultures, AngII through the AT1 receptor is able to promote
hypertrophy of the embryonic, neonate, and adult cardio-
myocytes.38 This effect is transduced by Gq-dependent and
independent signaling pathways already described for
VSMC.20 The additional beneficial effect of RAS blockers
on heart failure in comparison to other antihypertensive
drugs which reduce to the same extend cardiac overload
suggest a specific role of local activation of AT1 receptor in
heart failure development.
On the other hand, several studies indicate that AT1
receptor activation has no central role in hypertensive cardiac
hypertrophy. In vitro studies indicate that there is no
difference in extracellular signal-regulated kinase activation
after cell stretching in cardiomyocytes of AT1AWT and KO
mice.13 Similarly, cardiac overload produced by aortic
banding induces identical cardiac hypertrophy in AT1AWT
and KO mice.13 Additional evidence comes from the kidney
crosstransplantation experiments, which indicate that AngII-
induced cardiac hypertrophy can be observed in animals
expressing AT1AR only in the kidney.
15 Therefore, it seems
very unlikely that isolated activation of the cardiac AT1
receptor may induce cardiac hypertrophy. There is no
obvious cardiac hypertrophy and no development of systolic
heart failure in AT1AMUT mice.
5 A moderate increase of
heart weight is observed in old AT1AMUT male mice and
seems to be correlated to the BP level (Table 1). In spite of
these very modest changes, the activated receptor stimulates
clearly the production of BNP in the heart of these animals.
Conversely, strong evidence has been accumulated to
indicate that AngII by activation of the AT1 receptor
stimulates cardiac fibroblasts to produce ECM components,
whereas AT2R activation may have opposite effects. In vitro,
AngII stimulates expression and production of collagens,
fibronectin, laminin, and many other components of the
ECM.39 This effect seems to be mediated, at least in part, by
increased production and autocrine effect of transforming
growth factor-b. Accumulation of the ECM components in
the heart is also the consequence of decreased production and
activity of matrix metalloproteases such as MMP-1.
The role of AT1 activation in cardiac fibrosis development
is further confirmed in animal models of hypertension and in
hypertensive patients. The cardiac fibrosis observed in
spontaneous hypertensive rats is reversed by ARB but not
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hydralazine, despite similar BP reductions.40 In a limited
study performed in diabetic patients, echographic parameters
of diastolic function and fibrosis biomarkers were improved
after ARB treatment.41
Finally, these observations were confirmed in AT1AMUT
mice (Table 1). Despite a modest increase of BP, these
animals develop an early and progressive cardiac fibrosis,
observed both at the morphological level (Figure 1) and at
the ECM gene level (fourfold increase of the a1-collagen
expression). This cardiac fibrosis results in alteration of
diastolic function, which is observed in 5-month-old animals
and is more pronounced in 1-year-old animals.5 At the
present time, it is not clear if this cardiac fibrosis is the
consequence of AT1AR chronic activation in the heart or the
modest BP elevation. As already discussed, both factors have
been previously demonstrated to be potentially involved in
the development of cardiac fibrosis, but at a high level of
stimulation (that is major hypertension, AngII perfusion, and
so on). Experiments in progress, where AT1AMUT mice are
treated with an antihypertensive drug (calcium channel
blocker), which reduces BP without modifying AT1A receptor
activation, will answer this question in the near future.
In conclusion, if there is clear evidence that AngII by
activation of AT1 receptor is able to promote growth
and stimulate EMC production in cardiac fibroblasts,
cardiomyocytes, and VSMC, the precise role of AT1 receptor
activation versus hypertension in the development of
cardiovascular diseases is still a matter of debate. In practice,
answer to this question is important as it will indicate that
RAS inhibitors may have beneficial actions on cardiovascular
tissues independently of their actions in lowering BP, which is
strongly suggested by a wide number of large-scale trials. The
recent development of an animal model expressing perma-
nently activated AT1A receptors instead of the WT receptors
allows to dissociate the tissular effects of AT1A activation
from its effects on BP and to eliminate the interfering effects
of AT2 receptors, bradykinin system, and aldosterone actions.
This is and it will be the perfect model to answer the question
of the role of AT1 activation in the development of cardiac
hypertrophy, heart failure, arrhythmia, cardiovascular fibro-
sis, and atherosclerosis.
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